The New England Comparative Effectiveness Public Advisory Council (New England CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The New England CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the New England CEPAC process, and find out how topics are selected.
New England CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the New England CEPAC must meet ICER’s criteria for Conflict of Interest.
The box below provides information on the topic of the next meeting of the New England CEPAC. For more information about past and other upcoming meetings, see the box to the right.
The Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115
The New England CEPAC will convene in March 2017 to discuss ICER's report on treatments for rheumatoid arthritis.
Plaque psoriasis is a common disease that causes red, scaly, raised lesions on the skin, most commonly on the elbows, knees, scalp, and back. Psoriasis affects about 2% of the population and significantly decreases health-related quality of life, particularly if lesions are in areas that can affect daily functioning (e.g., the hands or soles of the feet) or affect social functioning (e.g., the face). Psoriasis is a chronic inflammatory condition that is associated with systemic diseases including psoriatic arthritis, other autoimmune diseases, the metabolic syndrome, and cardiovascular disease.
Interventions of interest:
- Adalimumab (Humira®, AbbVie)
- Etanercept (Enbrel®, Amgen, Inc.)
- Infliximab (Remicade®, Janssen)
Anti IL-17A agents:
- Secukinumab (Cosentyx®, Novartis)
- Ixekizumab (Taltz®, Eli Lilly and Co.)
- Brodalumab (Valeant Pharmaceuticals and AstraZeneca)
Anti IL-12/13 agent:
- Ustekinumab (Stelara®, Janssen)
- Apremilast (Otezla®, Celgene)